The decrease in apoAII-ATQ/AT relative to healthy controls was particularly dramatic in patients with IDACP, pancreatic diseases other than IDACP, cholangiocarcinoma, and duodenal carcinoma (Fig. 4A and Supplemental Table 3). This evidence concerns the gene APOA2 and pancreas disorder.